Idera Pharmaceuticals plans $75 million public offering shares

Company’s stock last closed at $4.02 per share

By Susanna Moon

Chicago, Feb. 9 – Idera Pharmaceuticals, Inc. plans to offer $75 million shares of its common stock, according to a 424B3 filing with the Securities and Exchange Commission.

Goldman, Sachs & Co. and J.P. Morgan Securities LLC are the underwriters.

The company’s stock (Nasdaq: IDRA) last closed at $4.02 per share on Feb. 6.

The company said that entities affiliated with two of its directors, Julian C. Baker and Kelvin M. Neu, have indicated an interest in purchasing up to $20 million of the shares.

Idera, based in Cambridge, Mass., develops targeted immune therapies based on the modulation of Toll-like receptors.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.